OBJECTIVES: Examine baseline treatment patterns and persistence among patients diagnosed with metastatic colorectal cancer (mCRC) or Gastrointestinal stromal tumor (GIST) and treated with Stivarga^® (regorafenib). METHODS: Adult patients treated with Stivarga from 9/27/12-7/31/13 were identified from a large national US claims database. Patients were retained if they were continuously enrolled in the health plan for ≥6 months before the initial (index) fill (baseline period) and ≥1 month after the index fill (follow-up period). Patients were required to be diagnosed with mCRC or GIST, be 18+ years old, and have non-missing demographic information. Follow-up persistence with Stivarga was identified based on a gap in therapy of at least 30 days. The use of chemotherapy in the baseline, the last regimen received before initiating Stivarga, and the amount of time between receipt of last chemotherapy and Stivarga initiation was identified. RESULTS: